EFFECT OF RECOMBINANT HUMAN GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTOR ON MYELOPOIESIS IN THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME
EFFECT OF RECOMBINANT HUMAN GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTOR ON MYELOPOIESIS IN THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME
复制标题
DOI：
10.1056/nejm198709033171003
复制
发表时间：
1987-09-03
影响因子：
158.5
通讯作者：
GOLDE, DW
中科院分区：
文献类型：
--
作者：
GROOPMAN, JE;MITSUYASU, RT;GOLDE, DW
我们对16名患有获得性免疫缺陷综合征（AIDS）和白细胞减少症（2225 ± 100）的患者给予重组（生物合成）人粒细胞-巨噬细胞集落刺激因子（GM-CSF）。614个细胞/微升[平均值±。SD]）。每例患者首先接受单次静脉给药; 48小时后开始连续14天静脉输注该药物。所用剂量为1.3 × 104。103（n = 4），2.6x. 103（n = 4），5.2x. 103（n = 4），1.0 × 103（n = 4），104（n = 3），或2.0 × 104（n = 3）。104（n = 1）U/kg体重/天。重组GM-CSF给药导致循环白细胞呈剂量依赖性增加，循环中性粒细胞、嗜酸性粒细胞和单核细胞增加。峰值白细胞计数范围为4575 ± 1000。在最低剂量下每微升2397个细胞，在接受最高剂量的患者中为48，700个细胞。在一些患者中观察到轻度副作用，如低热、肌痛、静脉炎和潮红;没有危及生命的毒性反应。我们的数据表明，重组人GM-CSF是良好的耐受性和生物活性的白细胞减少患者与艾滋病。增加循环白细胞数量和功能的策略可能会降低这些和其他白细胞减少症患者感染的发病率和死亡率。
We administered recombinant (biosynthetic) human granulocyte-macrophage colony-stimulating factor (GM-CSF) to 16 patients with the acquired immunodeficiency syndrome (AIDS) and leukopenia (2225 .+-. 614 cells per microliter [mean .+-. SD]). Each patient first received a single intravenous dose; 48 hour later a 14-day continuous intravenous infusion of the agent was begun. The doses used were 1.3 .times. 103 (n = 4), 2.6 .times. 103 (n = 4), 5.2 .times. 103 (n = 4), 1.0 .times. 104 (n = 3), or 2.0 .times. 104 (n = 1) U per kilogram of body weight per day. Administration of recombinant GM-CSF resulted in dose-dependent increases in circulating leukocytes and in increases in circulating neutrophils, eosinophils, and monocytes. The peak leukocyte count ranged from 4575 .+-. 2397 cells per microliter at the lowest dose, to 48,700 in the patient receiving the highest dose. Mild side effects.sbd.low-grade fever, myalgia, phlebitis, and flushing.sbd.were observed in some patients; there were no life-threatening toxic reactions. Our data demonstrate that recombinant human GM-CSF is well tolerated and biologically active in leukopenic patients with AIDS. Strategies to increase the number and function of circulating leukocytes may reduce the morbidity and mortality of infections in these and other patients with leukopenia.